The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Repeat infusions of CD19 CAR-T
Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, talks on the deepening of responses in patients previously treated with CD19 CAR-T cells by using repeated infusions of the cellular therapy. Dr Gauthier goes on to outline how the use of fully humanized CAR-T cells may reduce immunogenicity. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
